ArticleJournal of nanobiotechnology2026
Exosome-mediated Piezo1 activation in 3D-printed titanium scaffolds promotes repair of femoral head osteonecrosis.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
Osteonecrosis of the femoral head (ONFH) is a debilitating bone disorder characterized by ischemic degeneration with limited therapeutic options. Piezo1, a mechanosensitive ion channel, transduces physical stimuli into intracellular signals regulating osteogenesis and angiogenesis. Here, we developed a 3D-printed Ti6Al4V scaffold conformally coated with photocrosslinked hyaluronic acid hydrogel that retains and releases Piezo1-engineered exosomes (P-Exos), forming a hybrid construct (P-Exos@HAMA/Ti) with cancellous-bone-like stiffness and sustained bioactivity. In vitro studies demonstrated that P-Exos enhanced BMSC viability, migration, and osteogenic differentiation (ALP/ARS; Runx2, Osterix, OCN) while promoting endothelial proliferation and network formation (CD31, VEGFA). RNA-seq and mechanistic validation revealed Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.